Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 70 CIRCULATE
2024-515297-27-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in colon adenocarcinoma and rectal adenocarcinoma (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: 3-year disease-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2024-515297-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515297-27-00.